ANAB EBITDA | ANAPTYSBIO, INC.

ANAPTYSBIO, INC. (ANAB) EBITDA

2026-03-31: Basis Reported; EBITDA -$34.51M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA $67.03M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA $35.12M*; Operating income $34.70M; Depreciation and amortization $418.00K*.
2025-06-30: Basis Reported; EBITDA -$26.31M*; Operating income -$26.17M; Depreciation and amortization -$136.00K*.

Complete source-backed ebitda history.

Available history: 2015-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-03-31	Reported	-$34.51M	(m)	(m)	(m)	-135.03%	$17.00K	-$25.92M	(m)	(m)	(m)	$40.00K
2025-12-31	Reported	$67.03M	(m)	(m)	(m)	61.92%	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	$35.12M*	$34.70M	$418.00K*	$76.32M	46.02%*	$12.00K*	-$27.36M*	(m)	$31.41M	(m)	$0.00
2025-06-30	Reported	-$26.31M*	-$26.17M	-$136.00K*	$22.26M	-118.16%*	$39.00K*	-$40.24M*	(m)	$37.82M	(m)	$39.00K
2025-03-31	Reported	-$27.39M	(m)	(m)	(m)	-98.64%	$35.00K	-$10.70M	(m)	$41.18M	(m)	$44.00K
2024-12-31	Reported	-$9.53M	(m)	(m)	(m)	-22.09%	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$22.61M*	-$22.76M	$144.00K*	$30.02M	-75.33%*	$35.00K*	-$10.09M*	(m)	$42.21M	(m)	$0.00
2024-06-30	Reported	-$40.17M*	-$40.32M	$154.00K*	$10.97M	-366.12%*	$33.00K*	-$21.32M*	(m)	$42.00M	(m)	$9.00K
2024-03-31	Reported	-$42.04M	(m)	(m)	(m)	-585.57%	$27.00K	-$37.25M	(m)	$37.04M	(m)	$0.00
2023-12-31	Reported	-$41.97M	(m)	(m)	(m)	-466.07%	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$37.57M*	-$37.73M	$158.00K*	$3.32M	-1132.43%*	$162.00K*	-$36.47M*	(m)	$30.88M	(m)	$0.00
2023-06-30	Reported	-$39.98M*	-$40.14M	$163.00K*	$3.46M	-1155.49%*	$190.00K*	-$25.41M*	(m)	$32.92M	(m)	(m)
2023-03-31	Reported	-$44.24M	(m)	(m)	(m)	-3219.43%	$175.00K	-$24.57M	(m)	$34.96M	(m)	(m)
2022-12-31	Reported	-$25.79M	(m)	(m)	(m)	-378.80%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$29.47M*	-$29.63M	$166.00K*	$1.29M	-2278.96%*	$50.00K*	-$17.75M*	(m)	$22.06M	(m)	(m)
2022-06-30	Reported	-$27.64M*	-$27.80M	$163.00K*	$1.22M	-2272.70%*	$78.00K*	-$24.15M*	(m)	$20.84M	(m)	(m)
2022-03-31	Reported	-$31.59M	(m)	(m)	(m)	-3256.39%	$55.00K	-$21.01M	(m)	$22.52M	(m)	(m)
2021-12-31	Reported	-$30.99M	(m)	(m)	(m)	-3065.48%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$6.59M*	-$6.76M	$169.00K*	$20.89M	-31.57%*	$172.00K*	-$7.01M*	(m)	$22.22M	(m)	(m)
2021-06-30	Reported	-$373.00K*	-$533.00K	$160.00K*	$30.03M	-1.24%*	$863.00K*	$9.59M*	(m)	$25.31M	(m)	(m)
2021-03-31	Reported	-$18.24M	(m)	(m)	(m)	-162.14%	$317.00K	-$23.20M	(m)	$24.18M	(m)	(m)
2020-12-31	Reported	$33.49M	(m)	(m)	(m)	55.82%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$24.20M*	-$24.34M	$138.00K*	$0.00	(m)	$88.00K*	-$17.01M*	(m)	$19.54M	(m)	$0.00
2020-06-30	Reported	-$22.50M*	-$22.64M	$137.00K*	$0.00	(m)	$83.00K*	-$19.61M*	(m)	$17.95M	(m)	$0.00
2020-03-31	Reported	-$10.11M	(m)	(m)	(m)	-67.42%	$87.00K	-$15.11M	(m)	$20.97M	(m)	$0.00
2019-12-31	Reported	-$22.12M	(m)	(m)	(m)	-737.27%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$33.61M*	-$33.74M	$135.00K*	$0.00	(m)	$280.00K*	-$22.10M*	(m)	$29.93M	(m)	-$51.00K
2019-06-30	Reported	-$26.53M*	-$26.66M	$124.00K*	$5.00M	-530.66%*	$241.00K*	-$15.52M*	(m)	$27.35M	(m)	-$60.00K
2019-03-31	Reported	-$24.66M	(m)	(m)	(m)	(m)	$180.00K	-$16.10M	(m)	$20.63M	(m)	-$19.00K
2018-12-31	Reported	-$19.56M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$16.80M*	-$16.89M	$91.00K*	$5.00M	-335.92%*	$321.00K*	-$14.86M*	(m)	$17.88M	(m)	$0.00
2018-06-30	Reported	-$14.35M*	-$14.41M	$64.00K*	$0.00	(m)	$304.00K*	-$8.88M*	(m)	$10.58M	(m)	$0.00
2018-03-31	Reported	-$15.7M	(m)	(m)	(m)	(m)	$232.00K	-$12.48M	(m)	$11.81M	(m)	$0.00
2017-12-31	Reported	-$7.1M	(m)	(m)	(m)	-236.80%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$9.04M*	-$9.09M	$46.00K*	(m)	(m)	$13.00K*	-$3.89M*	(m)	$6.70M	(m)	(m)
2017-06-30	Reported	-$2.50M*	-$2.56M	$51.00K*	(m)	(m)	$68.00K*	-$2.64M*	(m)	$7.21M	(m)	(m)
2017-03-31	Reported	-$9.95M	(m)	(m)	(m)	(m)	$85.00K	-$8.10M	(m)	$7.93M	(m)	(m)
2016-12-31	Reported	-$3.12M	(m)	(m)	(m)	-113.14%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$1.02M*	-$1.07M	$58.00K*	(m)	(m)	$0.00*	-$3.07M*	(m)	$3.28M	(m)	(m)
2016-06-30	Reported	$2.42M*	$2.36M	$60.00K*	(m)	(m)	$14.00K*	$1.67M*	(m)	$2.33M	(m)	(m)
2016-03-31	Reported	-$1.08M	(m)	(m)	(m)	-22.24%	$35.00K	-$2.06M	(m)	$4.79M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	$48.46M	(m)	(m)	(m)	20.65%	$87.00K	$19.70M	(m)	(m)	(m)	$772.00K
2024-12-31	Reported	-$114.34M	(m)	(m)	(m)	-125.27%	$358.00K	-$135.34M	(m)	(m)	(m)	$158.00K
2023-12-31	Reported	-$163.76M	(m)	(m)	(m)	-954.47%	$807.00K	-$120.80M	(m)	(m)	(m)	-$4.00K
2022-12-31	Reported	-$114.48M	(m)	(m)	(m)	-1112.85%	$358.00K	-$73.59M	(m)	$88.80M	(m)	$24.00K
2021-12-31	Reported	-$56.2M	(m)	(m)	(m)	-88.95%	$1.37M	-$45.92M	(m)	$98.50M	(m)	$0.00
2020-12-31	Reported	-$23.32M	(m)	(m)	(m)	-31.09%	$569.00K	-$14.16M	(m)	$80.03M	(m)	$0.00
2020-09-30	Rolling	(m)	-$79.48M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$88.89M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$92.91M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$106.92M	(m)	(m)	(m)	-1336.48%	$805.00K	-$69.52M	(m)	$99.34M	(m)	-$152.00K
2019-12-31	Rolling	(m)	-$107.43M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$104.84M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$87.98M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$75.74M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$66.41M	(m)	(m)	(m)	-1328.14%	$1.06M	-$48.51M	(m)	$56.20M	(m)	-$192.00K
2018-12-31	Rolling	(m)	-$66.72M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$54.21M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$46.41M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$34.55M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$28.6M	(m)	(m)	(m)	-285.98%	$290.00K	-$19.44M	(m)	$29.44M	(m)	$0.00
2017-12-31	Rolling	(m)	-$28.78M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$24.80M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$16.79M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$11.87M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$2.79M	(m)	(m)	(m)	-16.73%	$50.00K	-$9.03M	(m)	$15.42M	(m)	$0.00
2016-12-31	Rolling	(m)	-$3.02M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$3.05M	(m)	(m)	(m)	-17.35%	$238.00K	-$9.69M	(m)	$17.30M	(m)	$139.00K

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Kailera Therapeutics, Inc. (KLRA)	United States	$1.552B
Innoviva, Inc. (INVA)	United States	$1.493B	4.62
Syndax Pharmaceuticals Inc (SNDX)	United States	$1.606B	-8.82
ArriVent BioPharma, Inc. (AVBP)	United States	$1.485B	-10.25
Rapport Therapeutics, Inc. (RAPP)	United States	$1.623B	-14.56
Stoke Therapeutics, Inc. (STOK)	United States	$1.630B	-9.82
Xeris Biopharma Holdings, Inc. (XERS)	United States	$1.632B	-80.10
Ultragenyx Pharmaceutical Inc. (RARE)	United States	$1.456B	-5.62
OMEROS CORP (OMER)	United States	$1.456B	5.50
Eton Pharmaceuticals, Inc. (ETON)	United States	$1.701B	80.74